Skip to main content
Category

Research

OBR Oncology
ResearchTreatments

Are New NSCLC Findings Practice Changing, or Is PFS Boost Not Enough?

*October 2023* Findings from the FLAURA2 study, presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, showed that chemotherapy added to osimertinib in the first-line setting significantly increased progression-free survival (PFS) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, without data…
laurabbook@gmail.com
December 24, 2023
MEDPAGE TODAY
ResearchTreatments

Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC

*September 2023* SINGAPORE -- Treatment with the novel antibody-drug conjugate patritumab deruxtecan (HER3-DXd) after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy resulted in "clinically meaningful and durable efficacy" in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), according to the phase II HERTHENA-Lung01 trial. Among the…
laurabbook@gmail.com
December 24, 2023
ResearchTreatments

Clinician Spotlight: Dr. Josh Reuss

*October 2023* This month we have the honor of featuring Dr. Josh Reuss, Assistant Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center Washington, DC. Dr. Reuss participated in the 2021 EGFR Resisters Research Summit and was a ‘Breakout Session’ winner for his research on A Phase II Open-label Study…
laurabbook@gmail.com
December 24, 2023
Springer Link
ResearchTreatments

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists

*September 2023* This podcast, for healthcare professionals (HCPs), patients, and patient advocates, is a discussion among a panel of two patients (and co-founders of the patient advocacy group EGFR Resisters, https://egfrcancer.org/) and two oncologists. The objective of the podcast is to explain the importance of biomarker testing for patients with EGFR-mutated non-small…
laurabbook@gmail.com
December 24, 2023
Onc Live
ResearchTreatments

FDA Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

*August 2023* A supplemental biologics license application (sBLA) seeking the expanded approval of amivantamab-vmjw (Rybrevant) in combination with carboplatin plus pemetrexed for use in the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations has been submitted to the FDA.1  …
laurabbook@gmail.com
September 29, 2023
Precision Oncology Connect
ResearchTreatments

Podcast: An Introduction to Molecular Testing

*July 2023* In this podcast, Dr Tracy Stockley, pathologist and geneticist, University Health Network, and Prof. David Hong, medical oncologist, MD Anderson, come together to provide an introduction to molecular testing. Listen as they discuss: Why identifying genetic alterations is so important How targeted therapies impact outcomes When to use molecular profiling…
laurabbook@gmail.com
September 29, 2023
Onc Live
ResearchTreatments

ADCs Offer Exciting Potential in Lung Cancer

*July 2023* Antibody-drug conjugates (ADC) represent one of the most exciting areas of ongoing development for the treatment of patients with non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), according to Karen Reckamp, MD, MS, during a presentation at the 24th Annual International Lung Cancer Congress®.1 “This is the…
laurabbook@gmail.com
September 29, 2023